Reversal of doxorubicin-impaired wound healing using Triad compound

Triad is composed of Na pyruvate, vitamin E, and unsaturated fatty acids. We found that Triad, administered orally or topically, reverses wound healing that is impaired by doxorubicin (Doxo) in rats. Rats given Doxo (6 mg/kg IV) were wounded with linear dermal incisions, and the wound-breaking strength (WBS) was compared among groups of rats differently treated with TRIAD. Five groups of five rats each were studied. Triad was given orally using a 20 per cent TRIAD/rat chow mixture and topically as a 50 per cent TRIAD/petroleum base salve administered daily. All groups were wounded at postoperative day 0, at which time Doxo was given to groups II-IV. Group IV was fed oral TRIAD 7 days prior to wounding and until POD 21. All wounds were harvested at POD 21, and the mean WBS of each group was obtained using an Instron Tensiometer. Doxorubicin impaired normal wound healing by 40 per cent. Oral TRIAD restored WBS in Doxo-treated rats to 88 per cent of control values; topical TRIAD restored WBS to 80 per cent of control values. Moreover, treatment with topical TRIAD and oral TRIAD increased the WBS by 30 per cent and 50 per cent when compared with Doxo-only-treated animals. In conclusion, TRIAD has been shown to restore wound healing to nearly normal levels in doxorubicin-impaired wounds.